Dimension Therapeutics Inc. (Nasdaq: DMTX) received an unsolicited acquisition offer from Ultragenyx Pharmaceutical (Nasdaq: RARE) for a premium of approximately $138 million. Shares of Dimension Therapeutics leaped $1.70 to close at $5.90 while Ultragenyx Pharmaceutical stock plunged $2.24 to close at $52.99.
